Search

everythinglearnresearchcommunity

for

Search:↓

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

Increasing the finasteride dosage from 1mg every other day to 1mg daily can cause increased shedding, which is normal as hair follicles adjust. Shedding may stabilize in a few weeks to months, and sticking with the new dosage could lead to better long-term results.

Dutasteride is considered more effective than finasteride for hair loss, with some users increasing the dose to 2.5mg daily for better results. Experiences vary, with some seeing regrowth and others not, and side effects are a concern.

OP increased their dutasteride dosage from 0.1mg to 0.5mg and initially saw regrowth but is now experiencing significant hair shedding. They are concerned if this shedding is normal or if they should revert to the lower dosage.

A user shared their experience with hair loss treatment using finasteride (1mg) and minoxidil (1ml), noting significant shedding phases but hoping for improvement. Shedding is a common synchronized effect of the treatment, which may desynchronize over time, potentially taking over 5 years.

Taking dutasteride daily at higher doses results in more effective DHT suppression compared to every other day dosing, due to its dose-dependent nature and long half-life. Even at lower doses, dutasteride is more effective than finasteride for hair loss.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

A user reported that taking 20mg copper and 200mcg selenium completely stopped their hair loss. The conversation is about hair loss treatments.

Users are experiencing hair shedding after initial improvement using treatments like Minoxidil, finasteride, and dutasteride. Shedding is seen as a sign of progress, but concerns arise when hair falls out again after a few months.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

Minoxidil's effectiveness varies due to differences in sulfotransferase enzyme levels in the scalp, affecting people with conditions like ASD, liver disease, and androgenic alopecia. Treatments like topical tretinoin, microneedling, and using minoxidil sulfate instead of regular minoxidil can improve results for those with low enzyme levels.

Shiseido's Dermal Sheath Cup (DSC) Hair Multiplication treatment is now available in Japan. Users discuss the treatment's availability and cost.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

A user taking 1.25mg finasteride and 2.5mg oral minoxidil for hair loss, questioning if the dosage is enough for scalp hair regrowth. Another user reassures that hair will regrow stronger after initial shedding.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

The user experienced varying results with different hair loss treatments, including finasteride, minoxidil, RU58841, and dutasteride, with recent increased shedding after switching to a higher dose of dutasteride. They suspect the shedding is due to the dutasteride dose increase and question the effectiveness of dutasteride tablets from India.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

The user has been using oral Dutasteride (.5mg) for 104 days and oral Minoxidil (.5mg) for about 2 months to address hair loss. Changes in hair appearance are noted, influenced by haircuts and dyeing, which affect the visibility of thinning areas.

MCL-1 is important for hair follicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.

A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

The user has been using finasteride, dutasteride, and minoxidil without success and is considering a comprehensive blood test to explore other causes of hair loss. They are unsure about the necessity and cost of the extensive tests and are seeking advice on whether to proceed with the full panel or focus on specific tests.

Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.

A user shared progress photos after 37 days of using 0.5mg dutasteride for hair loss at age 17. The discussion focuses on the effectiveness of this treatment.

The user is experiencing worsening hair loss despite using 0.5mg dutasteride, 2.5mg minoxidil, and Nizoral. They are seeking advice and reassurance from others who have faced similar issues.

Finasteride and dutasteride are essential for stopping hair loss, while natural remedies are ineffective. Minoxidil can be added if needed, but blocking DHT is crucial.

A manager told an employee to stop using minoxidil, fearing it could unintentionally cause hair growth in others. The conversation is filled with humorous and sarcastic responses, questioning the manager's logic and suggesting the employee continue using the treatment secretly.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.